Endometriosis therapy with medroxyprogesterone acetate
Roland, M.; Leisten, D.; Kane, R.
Journal of Reproductive Medicine 17(4): 249-252
1976
ISSN/ISBN: 0024-7758 PMID: 978656 Document Number: 108984
Document emailed within 1 workday
Related Documents
Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P. 2019: Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi Contraception 100(5): 402-405
Cheewadhanaraks, S. 2013: Cumulative recurrence rates of endometriosis-associated pain after long-term intramuscular depot medroxyprogesterone acetate therapy Journal of the Medical Association of Thailand 96(2): 140-143
Wong, A.Y.K.; Tang, L.C.H.; Chin, R.K.H. 2010: Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial Australian and New Zealand Journal of Obstetrics and Gynaecology 50(3): 273-279
Arowojolu, A.O. 2000: Treatment of endometriosis with depot medroxyprogesterone acetate: a preliminary experience African Journal of Medicine and Medical Sciences 29(1): 55-58
Cheewadhanaraks, S.; Choksuchat, C.; Dhanaworavibul, K.; Liabsuetrakul, T. 2012: Postoperative depot medroxyprogesterone acetate versus continuous oral contraceptive pills in the treatment of endometriosis-associated pain: a randomized comparative trial Gynecologic and Obstetric Investigation 74(2): 151-156
Telimaa, S.; Kauppila, A.; Rönnberg, L.; Suikkari, A.M.; Seppälä, M. 1989: Elevated serum levels of endometrial secretory protein PP14 in patients with advanced endometriosis. Suppression by treatment with danazol and high-dose medroxyprogesterone acetate American Journal of Obstetrics and Gynecology 161(4): 866-871
Nanda, K.; Amaral, E.; Hays, M.; Viscola, M.A.M.; Mehta, N.; Bahamondes, L. 2008: Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy Fertility and Sterility 90(4): 965-971
Lorenz, I.; Mechl, Z. 1985: Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer Neoplasma 32(1): 119-124
Cooper, A.J.; Sandhu, S.; Losztyn, S.; Cernovsky, Z. 1992: A double-blind placebo controlled trial of medroxyprogesterone acetate and cyproterone acetate with seven pedophiles Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 37(10): 687-693
Africander, D.J.; Storbeck, K.-H.; Hapgood, J.P. 2014: A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A) Journal of Steroid Biochemistry and Molecular Biology 143: 404-415
Mantovani, G.; Macciò, A.; Lai, P.; Massa, E.; Ghiani, M.; Santona, M.C. 1998: Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate Seminars in Oncology 25(2 Suppl 6: 45-52
Stachowiak, G.; Owczarek, D.; Połać, I.; Pertyński, T.; Jedrzejczyk, S. 1999: The influence of hormone replacement therapy containing transdermal 17-beta estradiol and oral medroxyprogesterone acetate on coagulation and fibrinolysis Ginekologia Polska 70(8): 527-533
Katakkar, S.B.; Franks, C.R. 1978: Chemo-hormonal therapy for metastatic renal cell carcinoma with adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate Cancer Treatment Reports 62(9): 1379-1380
Klaassen, D.J.; Rapp, E.F.; Hirte, W.E. 1976: Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women Cancer Treatment Reports 60(3): 251-253
Sica, G.; Iacopino, F.; Marini, L.; Robustelli della Cuna, G. 1992: Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines Clinical Therapeutics 14 Suppl A: 87-96
Tomasicchio, M.; Avenant, C.; Du Toit, A.; Ray, R.M.; Hapgood, J.P. 2013: The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor PLOS one 8(5): E62895
Takatsuka, Y.; Katoh, T.; Tsumura, I.; Kobayakawa, K.; Kawahara, T. 1992: Successful treatment of disseminated breast cancer with combination therapy of 5'-deoxy-5'-fluorouridine (5'-DFUR), medroxyprogesterone acetate (MPA) and cyclophosphamide (CPA) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(1): 107-110
Africander, D.; Louw, R.; Verhoog, N.; Noeth, D.; Hapgood, J.P. 2011: Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract Contraception 84(4): 423-435
Govender, Y.; Avenant, C.; Verhoog, N.J.D.; Ray, R.M.; Grantham, N.J.; Africander, D.; Hapgood, J.P. 2014: The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor Plos one 9(5): E96497